Available from: Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR et al (2021) GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis
During a mean follow-up of 10.6 months, adults receiving an SGLT2 inhibitor had a lower risk for a CV event than those receiving a DPP-IV inhibitor (HR = 0.72
At the same time, waste products are ushered out of tissues more efficiently
These broad estimates indicate the potential number of non-elderly adults who meet the clinical criteria for GLP-1 drugs, although employers and insurers may have more restrictive eligibility standards for coverage
Energy levels tend to bounce back after those first few weeks, as your body adjusts